Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Teclistamab - Genmab/Janssen Research & Development

Next Previous
Drug Profile

Teclistamab - Genmab/Janssen Research & Development

Alternative Names: BCMAxCD3 - Genmab/Janssen Research & Development; JNJ 7957; JNJ-64007957; Tebbei; tecbeili; Techbayri; Techvaili; teclistamab-cqyv; Tecvaili; TECVAYLI; Tekbeiri

Latest Information Update: 02 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab; Janssen Research & Development
  • Developer Genmab; Janssen Research & Development; Johnson & Johnson
  • Class Antineoplastics; Bispecific antibodies; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma

Most Recent Events

  • 26 Jun 2026 EMA's CHMP recommends approval of a Type II variation for teclistamab in combination with daratumumab for Multiple myeloma (Second-line therapy or greater, Combination therapy) European Union
  • 14 Jun 2026 Efficacy and adverse events data from the phase II ImmunoPRISM trial in Multiple myeloma released by Dana-Farber Cancer Institute
  • 02 Jun 2026 Updated adverse events and efficacy data from a phase-Ib/II RedirecTT-1 trial in Multiple myeloma presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top